Broadwood Partners, L.P. Acquires 34,296 Shares of STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical (NASDAQ:STAA - Get Free Report) major shareholder Broadwood Partners, L.P. acquired 34,296 shares of STAAR Surgical stock in a transaction dated Tuesday, March 25th. The stock was purchased at an average price of $17.44 per share, for a total transaction of $598,122.24. Following the completion of the acquisition, the insider now directly owns 12,319,691 shares in the company, valued at approximately $214,855,411.04. This represents a 0.28 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Thursday, March 27th, Broadwood Partners, L.P. acquired 3,620 shares of STAAR Surgical stock. The shares were acquired at an average cost of $17.48 per share, with a total value of $63,277.60.
• On Thursday, March 20th, Broadwood Partners, L.P. bought 108,720 shares of STAAR Surgical stock. The shares were acquired at an average cost of $17.96 per share, for a total transaction of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. purchased 93,124 shares of STAAR Surgical stock. The shares were bought at an average price of $17.54 per share, for a total transaction of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. bought 249,503 shares of STAAR Surgical stock. The stock was purchased at an average cost of $16.64 per share, with a total value of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. acquired 259,316 shares of STAAR Surgical stock. The shares were acquired at an average cost of $17.05 per share, for a total transaction of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. bought 36,532 shares of STAAR Surgical stock. The stock was bought at an average price of $15.49 per share, for a total transaction of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. bought 259,616 shares of STAAR Surgical stock. The stock was purchased at an average cost of $14.96 per share, for a total transaction of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. bought 8,221 shares of STAAR Surgical stock. The shares were acquired at an average cost of $21.50 per share, with a total value of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. purchased 21,155 shares of STAAR Surgical stock. The stock was acquired at an average price of $21.46 per share, for a total transaction of $453,986.30.

STAAR Surgical Stock Performance

STAA stock traded up $0.22 on Friday, reaching $17.79. The company had a trading volume of 818,576 shares, compared to its average volume of 780,730. The company's fifty day moving average is $19.43 and its 200 day moving average is $25.20. The company has a market cap of $877.49 million, a P/E ratio of -43.39 and a beta of 0.66. STAAR Surgical has a 1 year low of $13.50 and a 1 year high of $52.68.

Remove Ads

Wall Street Analyst Weigh In

Several brokerages have commented on STAA. Jefferies Financial Group lowered shares of STAAR Surgical from a "buy" rating to a "hold" rating in a research report on Wednesday, February 12th. William Blair lowered shares of STAAR Surgical from an "outperform" rating to a "market perform" rating in a research report on Wednesday, February 12th. BTIG Research lowered STAAR Surgical from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 12th. Stifel Nicolaus lowered their price target on STAAR Surgical from $38.00 to $20.00 and set a "buy" rating on the stock in a report on Wednesday, February 12th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of STAAR Surgical in a report on Thursday, February 27th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, STAAR Surgical presently has an average rating of "Hold" and an average price target of $25.29.

Institutional Trading of STAAR Surgical

Institutional investors and hedge funds have recently made changes to their positions in the stock. Broadwood Capital Inc. increased its position in STAAR Surgical by 0.7% during the 4th quarter. Broadwood Capital Inc. now owns 10,848,631 shares of the medical instruments supplier's stock worth $263,513,000 after purchasing an additional 80,200 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of STAAR Surgical by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier's stock worth $142,232,000 after purchasing an additional 319,441 shares during the last quarter. State Street Corp grew its holdings in shares of STAAR Surgical by 0.5% during the third quarter. State Street Corp now owns 1,940,567 shares of the medical instruments supplier's stock worth $72,092,000 after buying an additional 10,430 shares in the last quarter. Resona Asset Management Co. Ltd. acquired a new position in shares of STAAR Surgical in the fourth quarter valued at approximately $36,411,000. Finally, Geode Capital Management LLC raised its position in shares of STAAR Surgical by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier's stock valued at $43,641,000 after buying an additional 31,212 shares during the last quarter. 96.70% of the stock is currently owned by hedge funds and other institutional investors.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.